Abbott To Maintain Agreements With Cambridge Antibody Technology
This article was originally published in The Pink Sheet Daily
Abbott developed its RA therapy Humira and anti-interleukin-12 fully human monoclonal antibody using CAT technology.
You may also be interested in...
AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency